Skip to content
10-K

Annual Report

Orchestra BioMed Holdings, Inc. OBIO

0001104659-26-026754

← back to feed
Filed
Mar 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 10, 2026 58.52M sh
Shares Diluted FY 2025 · Dec 31, 2025 47.75M sh
Shares Diluted FY 2025 · Dec 31, 2024 36.82M sh
Capex FY 2025 · Dec 31, 2025 $489K
Capex FY 2025 · Dec 31, 2024 $289K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$48.96M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$50.56M
Long Term Debt FY 2025 · Dec 31, 2025 $15M
Cash And Equivalents FY 2025 · Dec 31, 2025 $34.69M
Cash And Equivalents FY 2025 · Dec 31, 2024 $22.26M
Current Liabilities FY 2025 · Dec 31, 2025 $16.74M
Current Liabilities FY 2025 · Dec 31, 2024 $16.21M
Total Liabilities FY 2025 · Dec 31, 2025 $51.48M
Total Liabilities FY 2025 · Dec 31, 2024 $43.22M
Current Assets FY 2025 · Dec 31, 2025 $107.91M
Current Assets FY 2025 · Dec 31, 2024 $69.17M
Total Assets FY 2025 · Dec 31, 2025 $114.86M
Total Assets FY 2025 · Dec 31, 2024 $76.17M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.11
Eps Diluted FY 2025 · Dec 31, 2024 −$1.66
Eps Basic FY 2025 · Dec 31, 2025 −$1.11
Eps Basic FY 2025 · Dec 31, 2024 −$1.66
Sga Expense FY 2025 · Dec 31, 2025 $26.91M
Sga Expense FY 2025 · Dec 31, 2024 $23.93M
Rd Expense FY 2025 · Dec 31, 2025 $58.19M
Rd Expense FY 2025 · Dec 31, 2024 $42.8M
Net Income FY 2025 · Dec 31, 2025 −$52.7M
Net Income FY 2025 · Dec 31, 2024 −$61.02M
Operating Income FY 2025 · Dec 31, 2025 −$51.81M
Operating Income FY 2025 · Dec 31, 2024 −$64.3M
Cost Of Revenue FY 2025 · Dec 31, 2025 $190K
Cost Of Revenue FY 2025 · Dec 31, 2024 $204K
Revenue FY 2025 · Dec 31, 2025 $33.48M
Revenue FY 2025 · Dec 31, 2024 $2.64M